Anbogen Therapeutics and University of Tokyo Launch Collaborative Research on ABT-301 Across Multiple Tumor Types
AI summaryAnbogen Therapeutics has entered a collaborative research agreement with The University of Tokyo to evaluate its HDAC inhibitor ABT-301 in multiple solid tumor types using comparative oncology models, aiming to accelerate clinical indication expansion.